Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1501796 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $7.01Day −0.57%Mkt cap $725M1Y +3.2%Off 52W high −26.5%Vol (1Y) 57.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,179 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.4% of sh out |
| Days to cover8.1d |
| 13F net flow (QoQ)+0.10% |
| Top-10 13F concentration76.6% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$112.4M |
| ROE−73.5% |
| ROIC−90.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+28.6% |
| 1Y+3.2% |
| 3Y−41.1% |
| Since incept. (ann.)−15.8% |
Total return through 2026-07-29 · series begins 2021-11-08. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)57.4% |
| Ann. volatility (3Y)62.3% |
| Sharpe (1Y)0.28 |
| Sharpe (3Y)0.03 |
| Max drawdown (1Y)−31.3% |
| Max drawdown (3Y)−59.1% |
| Beta (3Y vs SPY)0.75 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Matrix Capital Management Company, LP | 6.9M | $46M | 6.70% | +0.0% |
| Frazier Life Sciences Management, L.P. | 5.1M | $34M | 4.93% | +0.0% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.9M | $33M | 4.72% | +0.0% |
| Long Focus Capital Management, LLC | 4.6M | $31M | 4.47% | +0.0% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.4M | $29M | 4.23% | +0.0% |
| BlackRock, Inc. | 3.6M | $24M | 3.47% | +0.7% |
| Medicxi Ventures Management (Jersey) Ltd | 3.0M | $20M | 2.94% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $15M | 2.17% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.50 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.40 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$0.47 | — | — | — |
| 2025-03-31 | 2025-05-15 | −$0.55 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
